Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
November 9, 2021 9:06 AM ESTThe United States Federal Circuit Court of Appeals Affirmed Decision of the Patent Trial and Appeal Board that Mati Therapeutics Patent is Invalid
Mati Therapeutics Had Previously Alleged that DEXTENZA® Was Infringing Patent in Question
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent... More
